radiotracers

Binodenoson (WRC 0470) is a potent and selective A2A adenosine receptor agonist (KD=270 nM). Binodenoson is being developed as a short-acting coronary vasodilator as an adjunct to radiotracers for use in myocardial stress imaging[1].

QI-18 is a fibroblast activation protein (FAP) inhibitor with an IC50 value of 0.50 nM, offering a 6.5-fold increase in activity compared to UAMC-1110 (IC50 3.25 nM). It can be utilized in the synthesis of highly tumor-selective and high-dose radiotracers for the diagnosis and treatment of tumors.

PDE2A-IN-2 is a selective blood-brain barrier-permeable PDE2A inhibitor (Ki = 5.49 nM) with over 100-fold selectivity for other PDE subtypes. The 11C-labeled PDE2A-IN-2 can be utilized as a positron emission tomography (PET) tracer for imaging in neurodegenerative diseases. In vitro, PDE2A-IN-2 reduces the signal of radiotracers in PDE2A-rich areas, while in vivo, it shows lower binding affinity. It is applicable in research focused on neurodegenerative conditions.

WL12 is a peptide that targets and binds specifically to programmed death ligand 1 (PD-L1). It can be radiolabeled with various radionuclides to produce radiotracers, enabling the evaluation of PD-L1 expression in tumors [1].

DOTA-ADIBO TFA is a DOTA-derived bifunctional chelating agent (BFC) that facilitates drug conjugation through a catalyst-free, copper-free click reaction. It enables the construction of fusion chelator systems, and after Cu[64] modification, it is used for the synthesis of radiotracers. It is applied in positron emission tomography (PET) imaging of tumors expressing integrin αvβ6.